EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer

Mirko Bakula iD, Tvrtko Hudolin iD, Nikola Knezevic iD, Zoran Zimak iD, Jerko Andelic, Ilija Juric iD, Marija Gamulin, Milena Gnjidic, Zeljko Kastelan

Life · 22.06.2024 · 14 (7) · 789

DOI: 10.3390/life14070789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 22.06.2024. Verfasst von Mirko Bakula und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacillus Calmette-Guérin (BCG) therapy for patients with non-muscle invasive bladder cancer (NMIBC) faces limitations in efficacy and significant side effects, aggravated by a recent global shortage. In this prospective clinical study, we report the outcomes of sequential intravesical administration of gemcitabine and docetaxel (Gem/Doce) as a first-line treatment for BCG-naïve patients with high-risk NMIBC (HR NMIBC). From October 2019 until April 2022, we enrolled 52 patients and followed the treatment protocol set forth by the University of Iowa. Follow-up assessments were conducted every 3 months. In this cohort, 25 (48.1%) patients were diagnosed with high-grade T1 (T1HG) bladder cancer, 10 (19.2%) patients had carcinoma in situ (CIS), and 17 (32.7%) patients had a combination of T1HG+CIS. The median time to first recurrence in the T1HG, CIS, and T1HG+CIS groups was 11, 10.5, and 8.8 months, respectively. The recurrence-free survival was 98.1%, 94.2%, and 80.8% at 6, 9, and 12 months, respectively. The rate of progression-free survival was 100%, 98.1%, and 92.3% at 6, 9, and 12 months, respectively. We demonstrated the safety and efficacy of Gem/Doce therapy in BCG-naïve patients with HR NMIBC during a one-year follow-up. Further research with extended follow-ups, as well as direct comparisons of Gem/Doce with other anticancer agents, is essential.

Schlagwörter

Stichwörter der Autor:innen

BCG shortageBCG-naïvedocetaxelgemcitabinenon-muscle invasive bladder cancer

Autor:innen und Institutionen

  • Department of Urology, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
  • School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia.
  • Department of Oncology, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.

ORCID-Profile: Mirko Bakula, Tvrtko Hudolin, Nikola Knezevic, Zoran Zimak, Ilija Juric

Zitieren

APA

Bakula, M., Hudolin, T., Knezevic, N., Zimak, Z., Andelic, J., Juric, I., Gamulin, M., Gnjidic, M., & Kastelan, Z. (2024). Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer. Life, 14(7), 789. https://doi.org/10.3390/life14070789

Vancouver

Bakula M, Hudolin T, Knezevic N, Zimak Z, Andelic J, Juric I, et al. Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer. Life. 2024;14(7):789. doi:10.3390/life14070789

BibTeX
@article{Bakula2024,
  author = {Bakula, Mirko and Hudolin, Tvrtko and Knezevic, Nikola and Zimak, Zoran and Andelic, Jerko and Juric, Ilija and Gamulin, Marija and Gnjidic, Milena and Kastelan, Zeljko},
  title = {Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer},
  journal = {Life},
  year = {2024},
  volume = {14},
  number = {7},
  pages = {789},
  doi = {10.3390/life14070789}
}
Kostenlos starten →